Dr. Mohammad Khalid Mojadidi, MD

Dr. Mojadidi practices at Ochsner Lafayette General Medical Center in Lafayette, Louisiana, part of Ochsner Health System.

Dr. Mojadidi's NPI, 1043571029, was assigned on June 6, 2012. Dr. Mojadidi holds Virginia license 0101264311.

Dr. Mojadidi's primary practice is Ochsner Lafayette General Medical Center, at 1214 Coolidge Avenue, Lafayette, LA 70503 in Lafayette Parish. The practice phone is (337) 289-7991.

Dr. Mojadidi's primary practice is Ochsner Lafayette General Medical Center in Lafayette, Louisiana, part of Ochsner Health System. Dr. Mojadidi is also affiliated with Carle Foundation Hospital. The medical group on file is Cardiovascular Institute of the South. Dmand AI also links Dr. Mojadidi to 3 more hospitals, 13 medical groups and 3 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mojadidi practices, 8 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Mojadidi's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Mojadidi is licensed in Virginia.

CMS data shows 493 Medicare services from Dr. Mojadidi across 8 procedure codes in 2024, for 351 Medicare patients. Medicare paid $31,125 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 351 Medicare patients who saw Dr. Mojadidi in 2024. The largest group is 75 to 84, with 121 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 27% are also on Medicaid. Their average risk score is 2.45, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mojadidi's median patient age at 65, with 40% women.

In 2024, Dr. Mojadidi wrote 135 Medicare Part D claims for 63 patients. 79% of them were for generic drugs. CMS names the drug for 25 of them, across 2 drugs with 11 or more claims each, at $19,129 in total drug cost. In 2023, CMS named 843 claims across 18 drugs.

Dr. Mojadidi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 15 general payments to Dr. Mojadidi from 7 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. AstraZeneca Pharmaceuticals LP paid the most, $424.